$LQDA

Manning Paul B sold $12.8M of LQDA (indirect holdings)

Manning Paul B sold 200,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $63.91 ($62.62–$64.42, $12.78M total) across 5 trades on 2026-06-04.

Original reporting
SEC EDGAR · Manning Paul B
Published Jun 8, 2026, 8:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 200,000 shares at ~$63.91 weighted average, totaling ~$12.78M, with holdings after sale of 798,335 shares.

02

Market read

This is a primary insider-transaction datapoint that can influence short-term sentiment, but the filing contains no new operational or financial catalyst.

03

What to watch

Form 4s often lack context (taxes, estate planning, diversification). Traders should cross-check whether other insiders or major holders are also selling/buying around the same period.

Relevance 7/10Novelty 8/10Timing: Filed June 8, 2026; sale executed June 4, 2026.

Background

The article reports an SEC Form 4 insider transaction for Liquidia Corp director Manning Paul B.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia director Manning Paul B sold $12.78M of LQDA shares via open-market transactions (Form 4), reducing holdings to 798,335 shares.

Expected impact

Likely limited/short-lived impact; any reaction would be sentiment-driven rather than a fundamental repricing catalyst.

Evidence & confidence

The disclosure is primary-source (Form 4) and sizable, but the article provides no accompanying company-specific news (earnings, guidance, trials, deals) and notes no 10b5-1 plan.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical signal provided.

None indicated.

None indicated.

Counterpoint

The sale may reflect diversification, liquidity needs, or pre-planned personal circumstances; without a 10b5-1 plan, it still doesn’t prove negative company outlook.

Key entities

  • Liquidia Corp

    Company whose director insider sale is disclosed on SEC Form 4.

  • Manning Paul B

    Director who sold 200,000 shares of LQDA across five trades on June 4, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient